


Express Mail Label No.: EJ770259431US

Date of Deposit: May 9, 2000

Attorney Docket No. 19705-001 (AMC-1)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Grasso *et al.*
ASSIGNEE: Albany Medical College
SERIAL NUMBER: 09/377,081
FILING DATE: August 19, 1999
FOR: LEPTIN-RELATED PEPTIDES

EXAMINER: Not Yet Assigned
ART UNIT: 1646

May 9, 2000
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

Other Prior Art – Non Patent Literature Documents:

- C6 Malendowics *et al.*, "Leptin(116-130) enhances the proliferative activity of immature rat adrenal cortex." *Medical Science Research* 27: 675-676 (1999).
- C7 Grasso *et al.*, "Inhibitory Effects of Leptin-Related Synthetic Peptide 116-130 on Food Intake and Body Weight Gain in Female C57BL/6J ob/ob Mice May Not Be Mediated by Peptide Activation of the Long Isoform of the Leptin Receptor." *Diabetes* 48:2204-2209 (1999).
- C8 Gonzalez *et al.*, "Effect of acute immunoneutralization of endogenous leptin on prolactin and LH secretion during the afternoon of pro-oestrus or in steroid-treated ovariectomized female rats." *Journal of Reproduction and Fertility* 118: 39-45 (2000).
- C9 Gonzalez *et al.*, "Leptin 116-130 Stimulates Prolactin and Luteinizing Hormone Secretion in Fasted Adult Male Rats." *Neuroendocrinology* 70:213-220 (1999).
- C10 Grasso *et al.* 1997 Eastern Great Lakes Endocrine Symposium. (Albany, NY) Poster Abstract. Nov. 3, 1997.
- C11 Grasso *et al.* 80th Annual Meeting of the Endocrine Society. Poster Abstract. 1998
- C12 Grasso *et al.* 81st Annual Meeting of the Endocrine Society, San Diego CA. Post Abstract. June 12-15, 1999.

This Information Disclosure Statement is being been filed:

☒ before the mailing date of a first Office Action on the merits in the above-identified case.
Accordingly, no fee or certification is required. 37 C.F.R. §1.97


APPLICANTS: Grasso *et al*
U.S.S.N.: 09/377,081

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 19705-001.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Kristin E. Konzak, Reg. No. 44,848
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: May 9, 2000

TRADOCs:1327681.1(SGG1011.DOC)